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  FOOT & ANKLE
A multicentre, randomized, parallel 
group, superiority study to compare 
the clinical effectiveness and cost- 
effectiveness of external frame versus 
internal locking plate for complete 
articular pilon fracture fixation in adults
PrOtOCOl fOr tHe ACtIVe rAndOmIzed COntrOlled trIAl
Aims
A pilon fracture is a severe ankle joint injury caused by high- energy trauma, typically affect-
ing men of working age. Although relatively uncommon (5% to 7% of all tibial fractures), 
this injury causes among the worst functional and health outcomes of any skeletal injury, 
with a high risk of serious complications and long- term disability, and with devastating con-
sequences on patients’ quality of life and financial prospects. Robust evidence to guide treat-
ment is currently lacking. This study aims to evaluate the clinical and cost- effectiveness of 
two surgical interventions that are most commonly used to treat pilon fractures.
Methods
A randomized controlled trial (RCT) of 334 adult patients diagnosed with a closed type C pi-
lon fracture will be conducted. Internal locking plate fixation will be compared with external 
frame fixation. The primary outcome and endpoint will be the Disability Rating Index (a pa-
tient self- reported assessment of physical disability) at 12 months. This will also be measured 
at baseline, three, six, and 24 months after randomization. Secondary outcomes include 
the Olerud and Molander Ankle Score (OMAS), the five- level EuroQol five- dimenison score 
(EQ- 5D- 5L), complications (including bone healing), resource use, work impact, and patient 
treatment preference. The acceptability of the treatments and study design to patients and 
health care professionals will be explored through qualitative methods.
Discussion
The two treatments being compared are the most commonly used for this injury, however 
there is uncertainty over which is most clinically and cost- effective. The Articular Pilon Frac-
ture (ACTIVE) Trial is a sufficiently powered and rigorously designed study to inform clinical 
decisions for the treatment of adults with this injury.
Cite this article: Bone Jt Open 2021;2-3:150–163.
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Introduction
A pilon fracture is a severe fracture of the distal 
end of the tibia, involving its weight- bearing 
articular surface at the ankle joint. It is caused by 
high- energy trauma, typically in men of working 
age (30s to 40s) as a result of a fall from a height 
or a traffic accident.1,2 Although pilon fractures 
are relatively uncommon—5% to 7% of all tibial 
fractures3-5—the risk of serious complications 
and long- term disability is high.2,6
the force required to create the fracture can 
lead to complex fracture configurations and 
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Table I. trial objectives.
1 to determine the effectiveness of external fixation versus internal fixation for the treatment of type C pilon fractures. this will be achieved through 
undertaking a parallel group multicentre rCt, using the primary outcome measure, the drI which is a patient- reported outcome measure assessing 
patient function at 3, 6, 12, and 24 months. the primary timepoint is assessment of drI at 12 months after randomization.
2 Undertake a 12- month internal pilot to obtain robust estimates of recruitment and confirm trial feasibility.
3 to explore barriers and facilitators during the pilot phase in order to optimize trial procedures and recruitment rates.
4 Undertake an economic evaluation to compare the cost- effectiveness of the two treatment options to determine the most efficient provision of future care 
and to describe the resource impact on the nHS for both treatments.
drI, disabilty rating Index; rCt, randomized controlled trial.
extensive soft- tissue damage that challenge repair.7 this is 
particularly the case for complete articular fractures (type C). 
Complications are common here, including deep infection, 
osteomyelitis, repeat unplanned surgery including arthrod-
esis, and amputation with the resultant impact on quality of 
life.8 Complications can result in readmission rates of up to 
50%.7,9,10 Post- traumatic arthritis also occurs in a high propor-
tion of patients even with adequate restoration of the joint.11 
treatment is lengthy and costly. People with this injury have 
among the worst functional and health outcomes for any 
skeletal injury and it can have persistent and devastating 
consequences on patients' health and financial prospects.11-14
type C pilon fractures are managed surgically using 
either external fixation or internal fixation. external fixa-
tion uses a fine wire frame and pins. Once the fracture is 
healed, the external fixation is removed. Internal fixation 
uses a plate and screws to stabilize the fracture. One- third 
of patients with external wires and pins develop infec-
tion.15 Although fine wire fixation is associated with a 
high superficial infection rate, it may lead to less deep 
infection, amputation, and lower secondary intervention 
rate compared with plates.16
the current choice of treatment is dependent on the 
surgeons’ training, expertise, and preferences for a partic-
ular treatment. reviews of the literature have consistently 
highlighted the need for high- quality research, partic-
ularly randomized controlled trials (rCts), to assess 
whether internal or external fixation is better for definitive 
management of these injuries.2,16,17
In order to address the evidence gap we will under-
take a rCt and economic evaluation to establish whether 
internal or external fixation is more clinical effectiveness 
and cost- effective for the management of type C pilon 
fractures. the injury’s rarity means that the involvement 
of the maximum numbers of centres possible that treat 
pilon fractures, a high rate of identification of eligible 
patients, and achieving a high recruitment rate are crit-
ical. We will therefore undertake an internal pilot and 
qualitative study in order to confirm feasibility of the 
main trial and ensure that trial processes are optimized 
before proceeding to the full trial.
Objectives
the aim of this study is to provide good quality evidence 
of the clinical and cost- effectiveness of internal plate 
fixation versus external fine wire fixation for the manage-
ment of type C closed pilon fractures of the distal tibia. 
the specific objectives are listed in table I.
Methods
Trial design. ACtIVe is a pragmatic, multicentre, rand-
omized controlled superiority trial with parallel groups, 
allocated on a 1:1 ratio. A concomitant economic evalua-
tion and a nested qualitative study with trial participants 
and healthcare professionals will be included. An internal 
12- month pilot study will confirm feasibility and inform 
trial processes.
Study setting. Patients will be recruited from nHS hospi-
tals across the UK, with recruitment from a minimum of 
23 sites required. Inclusion of international sites will also 
be explored.
Eligibility criteria. Included patients must meet all of the 
eligibility criteria, which are presented in table II. Patient 
eligibility for the study will be confirmed by a local con-
sultant orthopaedic surgeon or delegated clinician prior 
to their recruitment and recorded on the Case report 
form (Crf).
there will be no specific requirements in place on who 
can deliver the surgical procedures or routine physio-
therapy. this will be as per routine clinical practice at the 
participating centre. It will be confirmed during set- up 
that both interventions can be delivered at participating 
sites. the level of experience of surgeons and physiother-
apists treating trial participants will be recorded, in terms 
of their grade and the average number of pilon fracture 
patients they treat.
Interventions
Surgeons at recruiting centres will perform the surgery 
according to the patients’ random allocation.
Internal fixation. the ‘locking’ plate is inserted at the dis-
tal end of the tibia and passed under the skin on the sur-
face of the bone. the details of the reduction technique, 
the surgical approach, the type and position of the plate, 
the number and configuration of fixed- angle screws, and 
any supplementary device or technique will be at the dis-
cretion of the surgeon. the only stipulation is that fixed- 
angle screws must be used in at least some of the distal 
screw holes—this is standard practice with all distal tibia 
‘locking’ plates.
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Table II. Patient eligibility criteria
Inclusion criteria
Aged ≥ 16 years
Closed intra- articular pilon fracture of the distal tibia classified according to 
AO: AO 43- C1, C2 and C3 (complete articular), including patients with a 
bi- lateral pilon fracture and who have polytrauma.
the treating surgeon believes the patient will benefit from surgical fixation.
Exclusion criteria
> 21 days since injury
Previous failed fixation
Pathological fracture
Pre- existing (pre- injury) skin condition which precludes open surgery
Patient is/would be unable to understand instructions for treatment
External fixation. A limited minimally invasive open re-
duction and fixation of articular segment is undertaken. 
Once the articular segment is stabilized, the circular fixa-
tor is applied to the bone. Incision site, number and con-
figuration of screws, and number of rings, wires, and half 
pins will depend on the fracture configuration and will be 
at the discretion of the surgeon. Occasionally, synthetic/
iliac crest bone grafts may be necessary and circular fixa-
tor will have to extend across the ankle, which again will 
be left at the discretion of surgeon.
Physiotherapy. All participants will receive standardized, 
written physiotherapy advice detailing the exercises they 
need to perform for rehabilitation following their injury. 
In this pragmatic trial, any other rehabilitation input in-
cluding and beyond written physiotherapy advice will 
be left to the discretion of the clinical team. data on re-
habilitation will be collected using patient- completed 
questionnaires at three, six, 12, and 24 months post- 
randomization, as well as in a specific hospital Crf.
Primary outcomes. the primary outcome measure is 
the disability rating Index (drI) at 12 months post- 
randomization. the drI is a validated patient- reported 
outcome measure questionnaire.18 It consists of a 12- 
item visual analogue scale questionnaire assessing the 
patients’ own rating of their disability specifically related 
to the lower limb (drI; score range, 0 (no disability) to 
100 (complete disability)). these data will be collected 
at baseline, three, six, 12, and 24 months follow- up post- 
randomization. Baseline assessment will ask participants 
about their functioning before their injury and before 
their surgery.
Secondary outcomes. these will be assessed at baseline, 
3, 6, 12, and 24 months post- randomization unless oth-
erwise stated: the Olerud and molander Ankle Score 
(OmAS) is an established nine- item, patient- reported 
outcome measure developed and validated for use in 
clinical trials assessing symptoms following ankle frac-
ture.19 It contains items assessing pain and various activ-
ities of daily living. Item responses are each scored from 
0 to 25, with 0 representing the most severe state. raw 
scale scores are then converted to a metric (0 to 100; 0 = 
most severe).19 At baseline, the OmAS will be collected 
once (patients will be asked to complete it thinking about 
the week before ankle fracture).
the five- level euroQol five- dimension questionnaire 
(eQ- 5d- 5l) is a validated measure of health- related 
quality of life assessed in terms of 5 dimensions and a 
separate visual analogue scale. the eQ- 5d- 5l will be 
scored according to the User Guide (eQ- 5d- 5l; utility 
score range from < 0 (where 0 is a health state equiv-
alent to death; negative values are equivalent to states 
worse than death) to 1 (full health)).20 eQ- 5d- 5l data will 
be collected twice at baseline: to assess patient health 
related quality of life on the day (after the injury), and 
for the week before injury. At baseline, the eQ- 5d- 5l will 
be collected before randomization by patients who have 
capacity to consent at that time; or at the earliest oppor-
tunity after randomization, by patients who consent 
having regained capacity.
data on all further surgical procedures and other 
complications will be collected. this includes deep 
wound infection (using Centres for disease Control and 
Prevention definition,21 superficial infection, pin site 
infection (defined using the ‘Good, Bad and Ugly’ pin 
site grading system),22 rehospitalization, blood clots, 
wound dehiscence, septic arthritis, and secondary 
interventions for nonunion). Also recorded will be an 
assessment of nonunion (defined as inability to heal as 
confirmed on radiographs/Ct scan or as a secondary 
intervention for failure to heal); malunion (defined by 
as standard measurement based on dror Paley’s tech-
nique,23 assessed from final radiographs at 12 months); 
and secondary arthritis in the ankle (assessed using the 
Kellgren and lawrence scale).24 routine imaging at 12 
months after the injury will be used for these assessments 
(anteroposterior and lateral tibia radiograph views, with a 
focus on the ankle) and/or when clinically indicated a Ct 
scan of the tibia, fibula, and/or ankle.
data concerning resource use and work impact will 
be collected to inform the economic evaluation from 
patient questionnaires and hospital records (e.g. length 
of hospital stay, rehospitalization, and return to work). 
Patients will be asked about their treatment preferences 
at baseline and at 12 months follow- up.
Participant timeline. Participants will be followed 
up at three, six, and 12 months post- randomization, 
with the primary endpoint being 12 months post- 
randomization. there will be an additional secondary 
outcome endpoint of 24- month follow- up for all pa-
tients recruited in the first 24 months of the trial (ap-
proximately two- thirds of the total sample) to help re-
duce costs and length of the trial.
figure  1 illustrates the overall schedule and flow of 
trial participants through the study, based on the recom-
mended figure in the Standard Protocol Items: recom-
mendations for Interventional trials (SPIrIt),25 from initial 
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Fig. 1
Overall schedule of events for the Articular Pilon fracture (ACtIVe) trial, from eligibility screening, enrolment, treatment and follow- up assessments. aPatient- 
reported outcome measures collected at baseline include the disability rating Index (drI), Olerud and molander Ankle Score (OmAS), and five- level euroQol 
five- dimension score (eQ- 5d- 5l). bPatient medical background includes details on whether the patient is diabetic or is immunosuppressed, and details of 
any polytrauma present at baseline. cAll trial patients will receive standardized written physiotherapy advice. Any further rehabilitation input throughout 
their treatment pathway will be at the discretion of the clinical team. dPhysiotherapy logbooks completed to record all rehabilitation delivery within the trust 
starting from enrolment. eAssessment for pin site infections will be made each time a patient with an external frame attends a hospital visit until the time that 
the frame is removed, generally before six months, and recorded on a specific Case report form (Crf). froutine imaging will be used to complete the bone 
healing assessment at 12 months post- randomization to assess for malunion, nonunion, and secondary arthritis.
eligibility screening, consent and randomization, treat-
ment delivery, and data collection timepoints.
Sample size. In order to detect a minimum clinically im-
portant difference of eight points on the drI (Sd 20)18,26,27 
with 90% power and 5% statistical significance, 133 par-
ticipants per group are required (calculated using nQuery 
software (Statsols, Ireland)). Accounting for 20% attrition 
at the primary endpoint of one- year follow- up, the total 
recruitment target is 334 participants (167 per arm).
Recruitment. Potentially eligible patients will be identi-
fied from orthopaedic trauma clinics or wards, intensive 
care units, and the emergency departments at participat-
ing centres. All patients with a suspected type C pilon 
fracture will be screened for eligibility by the research 
team at the centre. figure  2 outlines the pilon fracture 
treatment flowchart and how it fits into our recruitment 
plans for the trial.
Once patient eligibility is confirmed, a member of the 
patient’s direct care team will approach them about the 
study. the research nurse/associate will provide informa-
tion about the study including the participant informa-
tion sheet and information leaflet about pilon fractures. 
Patients will have the opportunity to ask questions of the 
surgeon and the local research team. A document will be 
available to sites that answers frequently asked questions 
patients may have about the treatment options. Consent 
will be sought for follow- up beyond the duration of the 
trial to allow the possibility of future long- term follow- up.
due to the nature of the injury and its treatment, some 
patients may be unconscious at the time of admission, all 
will be distracted by their injury and its implications, and 
may have been administered large doses of opiates for 
pain relief. In instances where informed consent cannot 
be obtained from the patient a personal or professional 
consultee will be consulted in line with the mental 
Capacity Act 2005 for patients recruited within england 
and Wales. differences in research legislation and legal 
frameworks around recruitment of adults with incapacity 
in Scotland and northern Ireland means that recruit-
ment via consultee will not be used in these countries. 
In instances where a personal or professional consultee 
has agreed on behalf of a patient to take part, formal 
written informed consent will be sought retrospectively 
from the patient for continuation in the trial at the earliest 
appropriate time. the primary outcome measure in the 
trial is a patient- reported outcome measure. therefore, 
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Fig. 2
Pilon fracture treatment flowchart.
participants who do not regain capacity or permanently 
lack capacity at three months following randomization 
(the time of the first follow- up data collection) will be 
withdrawn from the study.
Screening logs will be kept at each site throughout 
the trial to determine the number of patients assessed 
for eligibility, reasons for any exclusion, and reasons 
for non- consent. Additionally, screening logs will also 
record the type of pilon fractures seen (type C1, C2, 
and C3). When an eligible patient does not consent to 
take part, and where the patient is willing, a Crf will 
be completed by the research nurse (rn) to record the 
reason for this and their treatment plan. this informa-
tion should inform efforts to optimize recruitment.
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Fig. 3
Pilot study outcome data used in analysis and to inform trial continuation.
Within the UK we will explore setting up Patient Iden-
tification Centres (PICs), and a letter will be provided to 
trial centres to publicize the trial to referring hospitals. 
this is to manage treatment expectations of patients 
before their referral to the trial centres and to encourage 
the continued referral of patients through the normal 
care pathway. regional trauma networks will commu-
nicate to all emergency departments about the trial to 
encourage the referral of patients through the normal 
care pathway.
Internal pilot. A mixed methods internal 12- month pilot 
study will test assumptions about recruitment and con-
firm whether the trial is feasible. the internal pilot aims 
to: obtain robust estimates of recruitment and confirm 
trial feasibility; review the internal pilot recruitment tar-
gets and assumptions; provide descriptive data regard-
ing identification, eligibility (including fracture subtype 
C1, C2, and C3), consent, randomization and receipt 
of randomized treatment, for all patients screened; and 
identify and describe challenges to and facilitators of re-
cruitment as well as methods to optimize trial procedures 
and recruitment rates.
the proportion of eligible patients who were 
approached, recruited, and randomized will be calcu-
lated, and information on reasons for non- approach 
and non- consent will be collated. Surgeon equipoise 
will be monitored during recruitment by scanning 
reasons for exclusion during screening and reasons 
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Table III. list of ‘expected’ adverse events for the ACtIVe trial.
Wound complications (e.g. delayed healing)
Infection at the surgical site or adjacent joint
Pin site infection requiring procedure, antibiotics, or admission
damage to a nerve or blood vessel
Breakage of orthopaedic hardware
thromboembolic events
Secondary operations for or to prevent infection, malunion, nonunion, or 
for symptoms related to the metalwork
Wire breakage and removal / exchange of wire
Partial/complete frame removal
Chronic regional Pain Syndrome
Amputation
elective admissions to hospital for the ankle
Abnormal blood results related to an infection
for crossover following randomization that may reflect 
surgeon preferences.
A nested qualitative study will also be conducted and 
will include: semi- structured interviews with patients 
who agree to take part in the trial (n = 15 to 20) and who 
decline participation (n = 5 to 10); interviews with partic-
ipating surgeons and trial recruiters (n = 15 to 20); and 
audio recordings of recruitment consultations.
All patients considered eligible to participate in the 
main trial will be eligible for the qualitative study. Patient 
interviewees will be sampled to ensure maximum varia-
tion from the cohort of interviewees who are eligible for 
recruitment into the trial and will be based on age, sex, 
and responses to the quantitative questions relating to 
treatment preferences and reasons for non- consent into 
the trial. Staff who are directly involved in patient recruit-
ment will be invited to interview.
All interviews will be semistructured, conducted via 
telephone, and will follow a topic guide that was devel-
oped through discussion with the research team, Patient 
and Public Involvement (PPI) members, and surgeons 
with expertise in the area. Interviews will explore reasons 
for participation and non- participation, interventions, 
and trial processes. Particular attention will be given 
to exploring trial participants' and recruiters' views on 
randomization, treatment preferences, and the barriers 
and facilitators to running a full scale trial. Patient inter-
views will also explore the impact and acceptability of 
interventions and recovery in the context of patients’ 
daily lives.
All interviews and a selection of consultation record-
ings (from those declining and accepting participation) 
will be transcribed verbatim. data will be analyzed 
thematically following guidance as outlined by Braun 
and Clarke.28 At the end of the internal pilot, qualitative 
and quantitative data will be integrated and will inform 
whether the study progresses from internal pilot to full 
study.
Treatment allocation. following patient consent, ob-
tained by the clinical/research team at site, and com-
pletion of baseline forms, individual patients will be 
randomly allocated to treatment arms in a 1:1 ratio, 
using computer- generated random permuted blocks of 
random sizes, stratified by centre. randomization will 
be performed independently, either by telephone or via 
the internet, by York trials Unit (YtU) using a secure 
web- or telephone- based randomization service to en-
sure concealment of the allocation sequence. the rand-
omization service will confirm patient eligibility. Where 
patients have a bilateral pilon fracture, the treating sur-
geon will choose the worst injury to be used for the 
trial, prior to randomization.
the patient will be informed by the clinician of their 
treatment allocation. YtU will send patients and their 
general practitioner a letter about the trial and treatment 
allocation. As with many surgical trials, it is not feasible 
to blind patients, surgeons, or outcome assessors to their 
allocation. However, detection bias will be mitigated 
given that both groups will be receiving routinely avail-
able surgical treatments.
Data management
Data collection. data completed by trial participants will 
be collected via questionnaires or in clinics as part of rou-
tine care. data collected from the hospital will be record-
ed on paper Crfs by hospital staff. each trial participant 
will have a unique six- digit identification number that will 
be pre- recorded on all Crfs.
for the qualitative study, interviews will be conducted 
face- to- face, via telephone, or Skype according to the 
preferences of each interviewee. All interviews will be 
recorded with permission.
Participant retention. Several methods will be employed 
to keep participants informed and to minimize attrition. 
firstly, where patients need assistance completing ques-
tionnaires one of the study team can help them complete 
them over the telephone. A pre- notification letter will be 
sent two weeks before the follow- up questionnaire is due 
at three, six, 12, and 24 months, to help prime partici-
pants. A text message reminder will also be sent on the 
day patients are expected to receive the postal question-
naire at three, six, 12, and 24 months.29 two- and four- 
week reminders will also be sent. Where these methods 
fail, participants will be given the option to complete an 
abridged questionnaire (a minimum of the drI and eQ- 
5d- 5l) via telephone after the four- week reminder, which 
they will also be contacted about by SmS messaging. At 
3, 6, and 24 month follow- up, an unconditional incentive 
payment of £5 will be included to maximize the comple-
tion and return of questionnaires. At 12 months this will 
increase to £20 to also cover expenses for attending the 
hospital clinic to perform imaging to assess bone heal-
ing.30 Patient newsletters will be produced during the 
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Table IV. details of trial registration for ACtIVe as per the recommended World Health Organization trial registration data Set
trial registration ISrCtn98152560
date of registration 06/03/2018
funder information the national Institute for Health research Health technology Assessment programme (reference number: 
15/130/84)
Sponsor Hull University teaching Hospitals nHS trust
Scientific title external frame versus internal locking plate for articular pilon fracture fixation: a multicentre randomized 
controlled trial
Countries of recruitment england, Wales, Scotland, northern Ireland and also exploring recruitment internationally
Health condition(s) or problem(s) studied Closed pilon fracture of the tibia, classified AO 43 C
Intervention(s) Arm 1: Internal plate fixation (‘locking’ plate) Arm 2: external frame fixation (limited open reduction and 
articular fixation)
Key inclusion and exclusion criteria Inclusion criteria:
 Patients aged ≥ 16 years;
 With closed pilon fractures, classified AO 43 C which can be bi- lateral and patients with polytrauma;
 Where the treating surgeon believes the patient will benefit from surgical fixation.
exclusion criteria:
 Prior failed fixation;
 Pathological fracture;
 Patient is/would be unable to understand instructions for treatment
 more than 21 days since injury
 Pre- existing (pre- injury) skin condition which precludes open surgery
Study type Interventional
Allocation: randomized controlled trial with 1:1 allocation
Primary purpose: superiority study comparing clinical and cost- effectiveness of interventions
date of first enrolment march 2018
target sample size 334
recruitment status recruiting
Primary outcome drI at 12 months
Key secondary outcomes OmAS; drI; health- related quality of life (eQ- 5d- 5l); complications (including nonunion); resource use (e.g. 
impact on the nHS and productivity).
drI, disability rating Index; OmAS, Olerud- molander Ankle Score.
trial to keep the participants informed and engaged with 
the trial.31
An embedded rCt will be undertaken to evaluate the 
effectiveness of sending a ‘reply’ versus ‘no reply’ SmS 
text message reminder on the questionnaire response 
rate at the three- month follow- up.32
Data management. the patient questionnaires and hos-
pital Crfs will be designed using teleform software.33 
A secure electronic management system will be used to 
track participant recruitment and study status as well 
as Crf returns. data from scanned Crfs will be verified 
through cross- checking against the hard copy. to max-
imize data quality, on their return to YtU key variables 
in the hospital Crfs will be reviewed by a research data 
administrator for completion and accuracy, who will re-
solve any queries with the rn at the relevant site. On their 
immediate return to YtU, participant questionnaires will 
be checked for missing data. Where this happens, a trial 
coordinator will call the patient to complete any missing 
primary outcome data, and other missing data as feasible, 
over the telephone. As a duty of care, free- text responses 
in questionnaires will be checked immediately for any-
thing that indicates that the participant could be at risk 
of harm. Where this occurs, the Principal Investigator (PI) 
and rn will be notified via email. following these initial 
checks, all Crfs will undergo a scanning process within 
the teleform software, followed by second checking and 
validation against predetermined rules.
All data will be completely anonymized for purposes 
of analysis and any subsequent reports or publications. 
for the purposes of ongoing data management, once 
randomized, individual patients will only be identified by 
trial numbers.
Statistical analysis. full analyses will be detailed in a statis-
tical analysis plan (SAP) agreed by the independent data 
monitoring and ethics Committee (dmeC) prior to the 
end of data collection. Any exploratory analyses of sub- 
groups that are of clinical interest will be pre- specified 
in the SAP. this trial will be reported according to the 
Consolidated Standards of reporting trials (COnSOrt) 
guidelines for clinical trials.
Internal pilot. the recruitment rate and 95% confidence 
interval (CI) will be estimated from the data collected. 
data will also be summarized for the reasons already 
given for doing the internal pilot. results will be com-
pared against the study’s recruitment assumptions and 
progression targets, and continuation of the trial or rele-
vant modifications will be decided by the funding body. 
figure 3 displays how analyses from the internal pilot will 
contribute to progression onto the main trial.
Main trial. A COnSOrt diagram will be constructed to 
show the flow of participants through the study and 
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the outcome data on screening, recruitment, and re-
ceipt of randomly allocated treatment collected. the 
number of participants withdrawing from the trial will 
be summarized with reasons where available. Baseline 
characteristics will be presented by trial arm both for 
the trial population as randomized and for those pa-
tients included in the primary analysis, i.e. those who 
provided a drI score at three months, six months, or 
12 months, and had data on fracture type. Statistical 
analyses will be on intention to treat (Itt) basis with 
patients being analyzed in the groups to which they 
were randomized. Statistical significance will be at the 
5% level, and analyses will be conducted in the latest 
available version of Stata or similar statistical software. 
All trial outcomes will be reported descriptively by tri-
al arm at all time points at which they were collected. 
Continuous data will be summarized as means, stand-
ard deviations, medians, and ranges; categorical data 
will be summarized as frequencies and percentages.
the primary analysis model will be a covariance 
pattern mixed effect linear regression model, with drI 
scores at three, six, and 12 months follow- up as the 
dependent variable, adjusting for randomized treat-
ment arm, group by time interaction and fracture type 
(C1 or C2 vs C3) as fixed effects and including treating 
centre and patient as random effects. the model will 
account for similarities of scores by the same person 
by means of an appropriate covariance structure. the 
estimated treatment group differences at 12 months 
will be reported as the primary endpoint with 95% 
confidence interval and associated p- value. Secondary 
analyses of the primary outcome will include an esti-
mate of treatment group differences at three and six 
months from the same model. A separate model addi-
tionally including 24- month data will derive treatment 
group differences at that point. the overall treatment 
effect across all prior timepoints will be derived at 12 
and 24 months (equivalent to area under the curve 
estimates). A sensitivity analysis will be carried out to 
assess the impact of adjusting for the drI pre- injury and 
post- injury. missing values of the drI at baseline will be 
imputed using centre- specific means. the primary anal-
ysis model will then be repeated with the addition of 
terms adjusting for the drI pre- injury and post- injury.
the nature of missingness for outcome data will be 
explored and multiple imputation and/or deviations 
from the missing- at- random assumption considered if 
appropriate.
there will be two exploratory sub- group analyses of 
the primary outcome, to assess the effectiveness of the 
different treatments across different patient sub- groups. 
One will consider the impact of baseline patient prefer-
ences, whereby an interaction between treatment arm 
and patient preference (receipt of preferred treatment, 
non- preferred treatment, no prior preference) will be 
added to the primary analysis model. the other will 
consider fracture types (C1+ C2 vs C3), whereby an inter-
action between treatment arm and fracture type will be 
added into the primary analysis model. the p- values of 
the interactions will be reported. While there is insuffi-
cient statistical power for these interactions, they may 
help inform further research.
We will consider the impact that time to surgery has 
on the primary outcome by reporting drI scores descrip-
tively for the four patient groups formed by considering 
treatment allocation together with time to surgery (< two 
days vs two to seven days vs > seven days).
Secondary continuous patient- reported outcome 
measures will be analyzed in a similar manner to the 
primary analysis model. Binary secondary outcomes 
of additional procedures and complications will be 
analyzed graphically.34
Cost-effectiveness analysis. the economic evaluation will 
assess the relative cost- effectiveness of internal plate fix-
ation in comparison to external fine wire fixation for the 
treatment of type C pilon fractures of the distal tibia. 
the time horizon of the analysis will be two years, as per 
duration of the ACtIVe trial, and will follow a nHS and 
Personal Social Services (PSS) perspective. In addition, 
we will conduct a secondary analysis to explore the im-
pact of productivity costs and unpaid activities on cost- 
effectiveness results. Any pre- specified sub- group analy-
ses will be conducted based on the sub- groups defined 
by the statistical analysis.
the primary outcome for the economic analysis will be 
the additional cost per quality- adjusted life year (QAlY) 
gained of internal plate fixation compared to external 
fine wire. Hence the value for money will be estimated in 
terms of cost per QAlY following an Itt approach. data 
on resource use (surgical and secondary procedure costs 
and equipment; information on hospital stay; primary 
and secondary care appointments; patient out- of- pocket 
costs and impact on employment), and health outcomes 
will be collected prospectively during the analysis using 
self- reported questionnaires and hospital Crfs, as previ-
ously described. Costs relating to surgical procedures will 
be based on time in theatre, staff time, consumables and 
devices, and nights in hospital after the procedure.
A discount rate will be applied to all costs and QAlYs 
accrued after 12 months at a rate of 3.5% per annum 
in line with nICe guidance.35 Unit costs will be derived 
from established national costing sources such as nHS 
reference Cost databases,36 the Personal Social Services 
research Unit (PSSrU)37 costs of health and social care, 
and the British national formulary.38 Unit costs will be 
multiplied by resource use to obtain a total cost for 
each patient.
As previously stated, the eQ- 5d- 5l questionnaire 
will be used to measure the impact of the intervention 
on patient’s health related quality of life. the eQ- 5d 
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health states will be valued using a UK- based social 
tariff. QAlYs will be calculated by plotting the utility 
scores at each of the three timepoints and estimating 
the area under the curve.39
for the analysis, we will use regression methods 
following a bootstrap framework. the bootstrap’s main 
advantage is dealing with skewed data, which often char-
acterize economics data. Heterogeneity will be captured 
by including baseline prognostic factors in regressions 
that will inform the economic model. Selection of regres-
sion covariates will be in line with the statistical analyses. 
the pattern of missing data will be analyzed and handled 
by means of multiple imputation (mI).40 A range of sensi-
tivity analysis will be conducted to test the robustness 
of the results under different scenarios, including prob-
abilistic sensitivity analysis. the probability that each 
intervention is cost- effective will be reported at the cost- 
effectiveness thresholds applied by nICe of £20,000 to 
£30,000/QAlY,41 and also £13,000/QAlY as suggested by 
recent research.42,43
If the results are deemed appropriate (i.e. there is a 
non- dominant situation in the trial- based evaluation) a 
complementary analysis will be carried out to explore how 
the differences observed during the trial evolve beyond 
the study. for this projection, we will use a decision 
modelling approach to extrapolate the cost- effectiveness 
data observed in the trial to a lifetime horizon. A review 
of existing literature will be conducted to determine the 
existence of evidence of relevant treatments in the patient 
groups eligible for the ACtIVe trial that could be poten-
tially used in our model. full analyses will be detailed in a 
Health economic Analysis Plan (HeAP).
Monitoring
Data monitoring. A dmeC will be established, which will 
be chaired by a statistician, and be independent from the 
funding body, Sponsor, and trial team. their role will be 
to review accumulating safety, efficacy, quality, and com-
pliance data, and advise the Sponsor (directly or indirect-
ly) on the future management of the trial. Only the dmeC 
will have access to the unblinded comparative data from 
the study. A dmeC Charter has been agreed which they 
will work to.
no interim analyses for the trial are planned and there 
are no defined stopping guidelines. However, there will 
be an internal pilot study, data from which will be used 
by the dmeC and trial Steering Committee (tSC) to 
check the assumptions about the feasibility of the trial 
and its continuation, particularly concerning recruitment 
assumptions. these data will also contribute to the final 
analyses.
Risks and anticipated benefits. In the context of the lack 
of robust evidence to determine the best surgical inter-
vention for patients with these injuries, the risks are not 
increased through trial participation. However, there 
are potential risks associated with the surgery that par-
ticipants in both groups may be affected by: infection, 
bleeding, and damage to the adjacent structures such 
as nerves, blood vessels, and tendons. nevertheless, 
surgeons performing the interventions in this trial un-
dertake these as part of routine practice and are familiar 
with them. the research Governance framework/ UK 
Policy framework for Health and Social Care research44,45 
and mrC Good Clinical Practice Guidance46 will be ad-
hered to, and measures taken within the trial, such as 
the emphasis on good practice and standardized proto-
cols/care pathways throughout, are likely to reduce risk 
and could bring additional benefits.
Adverse event management. Adverse events are defined 
as any untoward medical occurrence in a clinical trial 
participant and may be a non- serious adverse event 
(Ae) or a serious adverse event (SAe). All SAes will be 
recorded and reported by the sites to the trial team 
within 24 hours of the investigator becoming aware of 
them. Once received, causality and expectedness will 
be confirmed by the Chief Investigator (CI). SAes that 
are deemed to be unexpected and related to the trial 
will be notified to the research ethics Committee (reC) 
and sponsor within 15 days. All (S)Aes will be report-
ed to the tSC and dmeC. for non- serious Aes, the tri-
al team will be notified within five days of the event 
being known. follow- up reports a month later will be 
reviewed by the CI to ensure that adequate action has 
been taken and progress made.
Only adverse event data related to treatment for the 
original injury, that are ‘unexpected’ will be collected, 
and only up until the 24- month follow- up. A list of 
expected adverse events that we will not report is given 
in table III. this is because these are well- known compli-
cations that will be recorded on other Crfs for the two 
routine surgical treatments that the specialist clinical care 
teams will be experienced in managing.
Auditing. Hull University teaching Hospitals nHS trust 
will be the sponsor for the study. data monitoring will 
be undertaken by the trial management Group (tmG), 
as well as the independent members of the tSC and 
dmeC, as previously detailed. this will be reported to 
the sponsor and regular progress reports will be sub-
mitted to the funding body. the study will be conduct-
ed in line with rigorous standards set out in the research 
Governance framework for Health and Social Care and 
the guidelines for Good Clinical Practice. the tmG will 
meet on a quarterly basis to review trial conduct and 
progress, with more frequent meetings as required.
Ethics and dissemination
Research Ethics Committee approval. reC approval was 
granted on 13 february 2018 (nreS Committee Yorkshire 
and the Humber – Bradford leeds). Health research 
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Authority (HrA) approval for the study was also granted 
on 13 february 2018.
Protocol amendments. Any amendments to the protocol 
during the course of the trial will be submitted for approv-
al by the reC/HrA as necessary, having been agreed with 
the funding body, Sponsor, tSC, dmeC, and the tmG 
as required. following approvals, amendments will be 
communicated to the participating sites for implementa-
tion in accordance with HrA approval and guidance. All 
amendments will be documented in the published final 
report to the funding body.
Consent. Written informed consent for the main trial 
and qualitative study will be obtained by appropriately 
trained research staff or clinicians at recruiting sites as per 
local requirements. A detailed patient information sheet 
for the main trial and qualitative element will be used, 
developed in collaboration with patient representatives, 
and potential risks and benefits clearly explained. Within 
the qualitative study, patient consent to audio- record re-
cruitment discussions with the research team will be ob-
tained as verbal consent, which will be audio- recorded 
prior to the discussion. Implicit consent will be taken from 
the research team by the return of completed recordings.
Patient confidentially. All participant data, including 
data from on qualitative interviews, will be assigned a 
unique coded trial Id number to maintain participant 
confidentiality. All paper records will be stored securely 
in locked cabinets in the University of York in areas with 
restricted access (i.e. alarmed areas, requiring key cards 
during working hours). After a period of time these will 
be transferred to a secure off- site storage facility below 
ground, where access is via a security controlled mine-
shaft with no outward markings to advertise its presence. 
electronic records will be anonymous of identifiable in-
formation and stored on a password- protected server.
recordings and transcripts from the qualitative study 
will be anonymized and stored on a password- protected 
computer for three years following completion of the 
study. Only the research team will have access to qual-
itative data. Consent forms will be kept in a locked filing 
cabinet, separate to the other data collected for the study. 
transfer of data to any external transcriber will be via the 
university- based secure web- based data transfer system.
Declarations of interest. Independent members of the 
dmeC and tSC will be required to provide written con-
firmation that they have no competing interests to de-
clare. HS is a paid consultant for Orthofix, as was nG 
(until the end of 2018). HS is also a paid consultant for 
Biocomposites and has received research grants from 
Smith & nephew, BBraun and dermol laboratories. nG 
has received educational grants from Smith & nephew, 
Orthofix and Biocomposites as part of a non- profit organ-
ization organizing educational events. HS is a member 
of Jllr editorial board. CH and mC are members of the 
UK national Institute for Health research (nIHr) Health 
technology Assessment (HtA) funding Board. Cmcd 
is a member of the nIHr HtA & eme Journal editorial 
Board. York trials Unit receives funding from the British 
Orthopaedic Association to support grant applications. 
these associations and grants have not in any way influ-
enced contribution to this study.
Access to data. Permission to access source data by study 
staff and for regulatory and audit purposes will be sought 
via the patient consent form, with an explicit explanation 
in the information sheet and consent discussion. external 
requests for data following completion of planned anal-
ysis and dissemination will be notified to the CI and 
Sponsor for consideration and approval before seeking 
confirmation from the funding body. Any data will be an-
onymized before secure transfer.
Ancillary and post-trial care. this is a pragmatic tri-
al, where the trial treatments are routinely available in 
the nHS, and are the most frequently used treatments. 
therefore any ancillary and post- trial care for the contin-
uing treatment of a pilon fracture should be accessible to 
all trial participants in discussion with their clinician. If a 
patient is harmed through third party negligence, they 
may have grounds for legal action and compensation 
against the sponsor and/or trial team (where harm results 
specifically from trial participation) or the nHS (where 
harm results from their clinical care).
Dissemination. the trial results will be disseminated to key 
stakeholders and patients in various ways: in a peer- reviewed 
journal; production of a Health technology Assessment 
(HtA) monograph; presentation at key national and inter-
national scientific meetings; generation of patient informa-
tion in conjunction with patient team member for “Shared 
decision making” based on findings and update the entry 
on Wikipedia47 and write the map of medicine48 entry on pi-
lon fractures management.
the full trial report will be submitted to the funding body 
for publication in an open access, peer- reviewed journal. the 
executive summary and copy of the trial report will be sent to 
nICe and other relevant bodies, including Clinical Commis-
sioning Groups, so that study findings can inform their delib-
erations and be translated into clinical practice nationally. 
the trial team will work with the relevant Speciality Advi-
sory Committees (SACs) to incorporate the findings into the 
training curriculum for clinicians who will undertake treat-
ment for pilon fractures.
A summary of the study report, written in lay language, 
will be produced and made available to participants, 
members of our user group and relevant patient- focused 
websites. the trial protocol is being made publically available 
in a peer- reviewed journal.
the International Committee of medical Journal editors 
will be used to inform criteria for authorship.49 Where 
criteria are not met, those who contributed to study design 
or drafting of research outputs will be acknowledged as 
contributors, with those solely involved in conducting 
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the trial (e.g. staff at recruiting sites) will be recognized as 
collaborators.
Discussion
this research will further knowledge on the clinical and cost- 
effectiveness of the two treatments most frequently used in 
routine care for the treatment of type C articular pilon frac-
tures, a skeletal injury with one of the worst functional and 
health outcomes. results will be disseminated through peer- 
reviewed publications and the evidence will help to inform 
clinical practice. As per SPIrIt recommendations for clinical 
trial protocols,25 table  IV displays key items from the trial 
registration data set in line with World Health Organization 
recommendations.
Take home message
  - Recent reviews of the literature and National Institute of 
Health and Care Excellence (NICE) treatment guidance have 
identified the need for robust randomized controlled trials to 
assess whether internal or external fixation is better for management of 
pilon fractures.
  - The outcome of this study will directly influence clinical decision- 
making and health policy by informing international and UK national 
guidance, improve outcomes for patients, and reduce the financial 
burden associated with the injury.
  - A systematic review by NICE identified no economic evaluations, 
which this study is addressing.
Twitter
Follow the ACTIVE Trial @active_trial
Follow the York Trials Unit @YorkTrialsUnit
Follow Oxford Trauma and Emergency Care @Oxford_Trauma
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